Navigation Links
Experimental drug prolongs life span in mice
Date:5/1/2014

CHICAGO --- Northwestern Medicine scientists have newly identified a protein's key role in cell and physiological aging and have developed in collaboration with Tohoku University in Japan -- an experimental drug that inhibits the protein's effect and prolonged the lifespan in a mouse model of accelerated aging.

The rapidly aging mice fed the experimental drug lived more than four times longer than a control group, and their lungs and vascular system were protected from accelerated aging, the new study reports.

The experimental drug could potentially be used to treat human diseases that cause accelerated aging such as chronic kidney disease, diabetes and HIV infection as well as the effects of cigarette smoking.

"A drug like this could help reduce complications in clinical conditions that reflect accelerated aging," said Douglas Vaughan, M.D., senior author of the study. "This had a very robust effect in terms of prolonging life span."

Vaughan is the chair of medicine and the Irving S. Cutter Professor at Northwestern University Feinberg School of Medicine and physician-in-chief at Northwestern Memorial Hospital.

This is a completely different target and different drug than anything else being investigated for potential effects in prolonging life, Vaughan noted.

While the experimental drug is in the early stages of testing, Vaughan said, "It makes sense that this might be one component of a cocktail of drugs or supplements that a person might take in the future to extend their healthy life."

The study was published April 28 in Proceedings of the National Academy of Sciences.

The experimental drug, TM5441, is one of only several chosen each year by the National Institute on Aging to be tested in its Interventions Testing Program, which investigates treatments with the potential to extend lifespan and delay disease in mice.

The discovery is the result of 25 years of research by Vaughan's lab.

When cells or tissue age -- called senescence -- they lose the ability to regenerate and secrete certain proteins, like a distinctive fingerprint. One of those proteins, PAI-1 (plasminogen activator inhibitor) has been the focus of Vaughan's research, originally as it relates to cardiovascular disease.

"We made the intellectual leap between a marker of senescence and physiological aging," Vaughan said. "We asked is this marker for cell aging one of the drivers or mechanisms of rapid physiological aging?"

For the study, he and colleagues used mice bred to be deficient in a gene (Klotho) that suppresses aging. These mice exhibit accelerated aging in the form of arteriosclerosis, neurodegeneration, osteoporosis and emphysema and have much shorter life spans than regular mice. Vaughan determined that these rapidly aging mice produce increased levels of PAI-1 in their blood and tissue.

Then scientists fed the rapidly aging mice TM5441 -- the experimental drug -- in their food every day. The result was a decrease in PAI-1 activity (the aging protein Vaughan's team had identified), which quadrupled the mice's life span and kept their organs healthy and functioning.

Northwestern scientists also genetically produced the same life prolonging results when they crossed the mice deficient in the age-suppressing gene with mice deficient in PAI-1. Importantly, partial genetic deficiency of PAI-1 and the experimental PAI-1 antagonist produced provided similar benefits in the mice, Vaughan noted.


'/>"/>

Contact: Marla Paul
marla-paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related medicine news :

1. Experimental drug shows promise for treatment-resistant leukemias
2. Diabetes drug shows promise in reducing Alzheimers disease in an experimental model
3. Experimental drug could enhance multiple myeloma and myeloid leukemia therapies
4. Experimental drug shows encouraging results in treating most common form of lung cancer
5. Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant
6. ASSURE study of experimental agent to raise HDL yields disappointing and surprising results
7. York physicists offer novel insight into experimental cancer treatment
8. Experimental Drug Shows Benefits Against Melanoma in Early Study
9. Experimental Drugs Show Promise Against Prostate Cancer
10. Experimental Drug Seems to Aid Memory in Mice With Alzheimers
11. Mayo Clinic finds experimental drug inhibits growth in all stages of common kidney cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, ... In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the ... have extremely low property-tax rates, which contributes to the relatively lower cost of ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., ... Solutions (VLMS), is pleased to announce the appointment ... member of its Board of Directors and Chairman ... VLMS enables life science companies to manage their ... use of paper in this process. Furthermore, ValGenesis ...
Breaking Medicine Technology: